Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Codiak Biosciences Inc (CDAK)

Codiak Biosciences Inc (CDAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,099
  • Shares Outstanding, K 36,830
  • Annual Sales, $ 22,940 K
  • Annual Income, $ -37,160 K
  • 60-Month Beta 3.71
  • Price/Sales 0.04
  • Price/Cash Flow N/A
  • Price/Book 0.05
Trade CDAK with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.43
  • Most Recent Earnings $-0.77 on 11/03/22
  • Next Earnings Date 05/04/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +277,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0532 +7.14%
on 04/04/23
0.6200 -90.81%
on 03/17/23
-0.4990 (-89.75%)
since 03/03/23
3-Month
0.0532 +7.14%
on 04/04/23
0.9378 -93.92%
on 02/03/23
-0.4580 (-88.93%)
since 01/04/23
52-Week
0.0532 +7.14%
on 04/04/23
6.9800 -99.18%
on 04/05/22
-6.9030 (-99.18%)
since 04/04/22

Most Recent Stories

More News
Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress

– Reported platform-validating initial data from Phase 1 studies of exoSTING™ and exoIL-12™; plans to initiate Phase 2 studies for both programs in 1H 2023...

CDAK : 0.0570 (-55.98%)
Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...

CDAK : 0.0570 (-55.98%)
Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022

CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...

CDAK : 0.0570 (-55.98%)
2 “Strong Buy” Penny Stocks That Could See Huge Long-Term Gains

The first half of 2022 was marked by concerns over inflation, rising interest rates and recession, with the S&P 500 registering its worst half year since 1970. However, not everyone is seeing dark times...

CDAK : 0.0570 (-55.98%)
OLMA : 10.67 (+2.50%)
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine

OSLO, Norway and CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences...

CDAK : 0.0570 (-55.98%)
Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™

– Codiak’s engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest...

CDAK : 0.0570 (-55.98%)
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress

– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1...

CDAK : 0.0570 (-55.98%)
Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

– Experienced oncology drug developer with more than two decades advancing treatments for solid tumors and hematologic malignancies joins Codiak leadership...

CDAK : 0.0570 (-55.98%)
Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine

– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak...

CDAK : 0.0570 (-55.98%)
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform

Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing....

AXLA : 0.4009 (-8.89%)
CDAK : 0.0570 (-55.98%)
DNLI : 21.30 (-2.02%)
EVLO : 0.0001 (unch)
FHTX : 5.62 (+3.31%)
MRNA : 115.95 (-0.96%)
OMGA : 1.89 (-8.70%)
RUBY : 0.0570 (+2.70%)
SANA : 5.22 (-2.43%)
MCRB : 0.7018 (+0.11%)
SGTX : 22.47 (-2.56%)

Business Summary

Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 0.1504
2nd Resistance Point 0.1302
1st Resistance Point 0.0936
Last Price 0.0570
1st Support Level 0.0368
2nd Support Level 0.0166
3rd Support Level N/A

See More

52-Week High 6.9800
Fibonacci 61.8% 4.3340
Fibonacci 50% 3.5166
Fibonacci 38.2% 2.6992
Last Price 0.0570
52-Week Low 0.0532

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar